IVY BLOCK
LOE Approachingbentoquatam
NDATOPICALLOTIONPriority Review
Approved
Aug 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 9h ago · AI intelligence enriched 2mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IVY BLOCK (bentoquatam) is a topical lotion formulation approved in 1996 for the prevention of allergic contact dermatitis caused by poison ivy, oak, and sumac. It functions as a barrier agent that physically blocks urushiol oil penetration into the skin before exposure to these plants. The drug represents a preventive, non-systemic approach to managing plant-induced allergic reactions.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%), suggesting defensive positioning and potential team consolidation.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
IVY BLOCK currently has zero linked job openings, reflecting its mature market position and approaching loss of exclusivity. Career opportunities on this product are limited and primarily focused on defending market share against generic erosion rather than driving growth.
Brand ManagerField Sales Representative
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.